Journal list Promote Sponsor
• database DOAJ indexed
Chinese Journal of Cancer Research
Hong Kong · Beijing Institute for Cancer...
workspace_premium - — Oncology lock Subscription · DOAJ

Chinese Journal of Cancer Research

Chinese Journal of Cancer Research is a journal indexed in SJR in Oncology and Cancer Research with an H index of 34. It has a best quartile of -. It is published in English.

ISSN: 1000-9604
Publisher: Beijing Institute for Cancer Research
Category: Oncology
Indexation: verifiedDOAJ
open_in_new Portal NPD menu_book Guidelines NPD
schedule CountryOfPapers database fields
SJR Impact Factor trending_up
0 -
H-index 34
Acceptance rate pie_chart
34%
Source Acceptance_Rate
Time to publication hourglass_top
NPD
Field NPD
Publication cost (APC) payments
NPD Subscription
Non-OA path NPD

Metrics

Scimago and CountryOfPapers database fields

DOAJ

SJR Impact

0

H-index

34

Docs (year)

9

Docs 3y

70

Total refs

464

Cites 3y

321

Citable 3y

66

Cites/Doc 2y

0

Ref/Doc

5156.0

Immediate OA

—

Embargoed OA

NPD

Non OA / Submission

—

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims
rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.
User
* Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Apoptotic B16-F1 cells coated with recombinant calreticulin mediated anti-tumor immune response in mice

View more

X-ray diagnosis of juxtacortical chondrosarcoma

View more

Cytogenetic study on a new epithelial cell line, HNE-1, derived from nasopharyngeal carcinoma

View more

Correlation of steroid hormone receptors and clinical pathological features with prognosis of human breast cancer

View more

Conditioned medium of human nasopharyngeal carcinoma epithelioid cell line cne1 contained the activities of transformed growth-inhibiting factors

View more

Comparative study of phosphotyrosyl protein phosphatase of mice normal liver, regenerating liver, and mice H22a hepatoma ascites cell

View more

Cloning and expression of Fab genes of anti-stomach cancer McAb 3G9 inE. coli

View more

Clinicopathological study on 3441 cases of benign and malignant ulcers

View more

Clinical application of chinese herbs remedies as immunomodulators in the treatment of cancer

View more

Clear cell chondrosarcoma of bone

View more

Changes of serum alpha fetoprotein before and after radioimmunotherapy in patients with hepatocellular carcinoma

View more

Carcinogenicity of fusarin C isolated fromFusarium moniliforme

View more
SHOW MORE ARTICLES

Assay of sensitivity of cancer cell to anticancer drug in glass capillaries

View more

A familial 46 XY gonadal dysgenesis and high incidence of embryonic gonadal tumors

View more

Antibody to oncogene protein product and its conjugate with ricin A-chain

View more

Analysis on epitopes of igm with monoclonal anti-isotypic and anti-idiotypic antibodies against IgM from B-cll

View more

An epidemiological evidence of multistage process of stomach cancer

View more

An approach improving long-term outcome of surgery for hepatocellular carcinoma: Analysis of 113 patients surviving more than five years

View more

Activation of nucleolar rrna gene transcription in lymphocytes by tumor promoters: Applies studies with in situ hybridization detected by fluorescent method

View more

A study of the characteristics of gamma-glutamyltranspeptidase of human esophageal cancer

View more

A rapid staining method showing AgNOR and DNA in pathological diagnosis

View more

A preliminary study on the relationship between murine IgE level and 3-methylcholanthrene induced fibrosarcoma

View more

A preliminary study on human chorionic gonadotropin receptor from gastric carcinoma

View more

A phase I trial of an oral subtype-selective histone deacetylase inhibitor, chidamide, in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer

View more

FAQs